Examen
Page URL: https://www.bionews.org.uk/page_95351

US starts formal investigation into CRISPR patents

18 January 2016
Appeared in BioNews 835

The CRISPR 'patent wars' have now officially kicked off in the USA, with formal proceedings to determine who controls key patents over the revolutionary genome-editing technology.

The US Patent and Trademark Office (USPTO) declared an 'interference procedure' on 11 January, under which it will collect evidence to determine who was the 'first to invent' CRISPR/Cas9.

Patents over CRISPR/Cas9 are currently the subject of a dispute between scientists at the University of California, Berkeley and the Broad Institute of MIT and Harvard, Massachusetts, both of whom are claiming rights over the technology (see BioNews 802 and 829).

The first set of patent rights was awarded to Professor Feng Zhang at the Broad Institute in April 2014 under a special accelerated review programme, even though a team at UC Berkeley led by Professors Jennifer Doudna and Emmanuelle Charpentier had submitted a patent application first, several months prior to those filed by the Broad Institute.

UC Berkeley asked the USPTO to investigate in April last year, with a patent judge declaring last week that a conflict did arise between patent applications over the technology, signalling the start of the interference procedure.  

GenomeWeb explains that the patents were filed when the USA operated a 'first to invent' system, only later moving to a 'first to file' system. It goes on to say that the USPTO has named UC Berkeley as the senior party in the proceedings, meaning that the Broad Institute will need to establish that it invented the technology first. It also means that UC Berkeley is responsible for starting discussions on attempts to settle the dispute.  

'This is such an important technology for the industry I just almost think that for the sake of the industry, settlement between the parties would make sense,' Dr Lisa Haile of law firm DLA Piper told Genetic Engineering & Biotechnology News. She added that it might be a couple of years before the USPTO makes a decision.  

Adam Mossoff, patent specialist at George Mason University School of Law, said these actions usually arise over very valuable patents. 'This patent, in particular, is ... a significantly huge advance in gene-editing technology, and this type of technology is the core of what has made the biotech revolution,' he said.

Jacob Sherkow of New York Law School said: 'This is an absolutely humungous biotech patent dispute.'

A case conference is scheduled for March, and the proceedings will be conducted by Judge Deborah Katz.

SOURCES & REFERENCES
Bitter fight over CRISPR patent heats up
Nature News |  12 January 2016
Control of CRISPR, biotech’s most promising breakthrough, is in dispute
The Washington Post |  13 January 2016
CRISPR Dispute to Be Decided by Patent Office
MIT Technology Review |  12 January 2016
Interference Proceeding Likely to Prolong CRISPR Patent Case
Genetic Engineering & Biotechnology News |  13 January 2016
USPTO Declares Interference Proceeding to Adjudicate CRISPR Patent Spat
GenomeWeb |  12 January 2016
RELATED ARTICLES FROM THE BIONEWS ARCHIVE
31 July 2017 - by Dr Rachel Brown 
The University of California has moved to appeal a decision of the US Patent Trial and Appeal Board over the use of CRISPR in eukaryotic cells...
20 February 2017 - by Ryan Ross 
The US Patent and Trademark Office has upheld the right of the Broad Institute of MIT and Harvard to the genome-editing tool CRISPR/Cas9...
12 December 2016 - by Antony Blackburn-Starza 
Oral arguments from lawyers acting for the Broad Institute and the University of California, Berkeley, in the high-profile CRISPR/Cas9 patent dispute have been heard in Virginia...
22 August 2016 - by Chee Hoe Low 
A former MIT visiting student who worked in the Zhang lab for nine months in 2011 has claimed that patents over the CRISPR genome-editing technology were 'mis-patented'...
8 February 2016 - by Cait McDonagh 
A biotechnology company co-founded by two leading scientists involved in developing the genome-editing technology, CRISPR/Cas9, has gone public, raising over $94 million in its initial share offering...
11 January 2016 - by Paul Waldron 
Researchers have improved the genome-editing technique CRISPR/Cas9, reducing errors to nearly undetectable levels, according to a new study...
30 November 2015 - by Dr Silvia Camporesi and Dr Lara Marks 
It is important to engage the public in the debate about genome editing as early as possible, and in a way that is as open as possible, to make sure that all possible voices are included...
23 November 2015 - by Dr James Legg 
On 26 October this year the CRISPR/Cas patent wars truly began with the filing of European oppositions against what appears to be the first patent granted in Europe for this revolutionary gene-editing technology....
18 May 2015 - by Ari Haque 
Patents for the gene-editing technology, CRISPR/Cas9, are the subject of a dispute between scientists at University of California, Berkeley and the Broad Institute of MIT and Harvard....
HAVE YOUR SAY
Log in to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions


Syndicate this story - click here to enquire about using this story.